- Home
- SQFT vs NXTS Comparison
SQFT vs NXTS Comparison
Compare SQFT & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFT | NXTS |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Agricultural Chemicals |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 2.1M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SQFT | NXTS |
|---|---|---|
| Price | $0.80 | $0.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.6K | ★ 182.6K |
| Earning Date | 11-11-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,814,708.00 | $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $0.50 |
| 52 Week High | $6.40 | $53.90 |
Technical Indicators
Market Signals| Indicator | SQFT | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 30.09 |
| Support Level | $0.74 | $0.50 |
| Resistance Level | $1.54 | $2.03 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 65.95 | 31.60 |
Price Performance
Historical ComparisonAbout SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.